IRVINE, Calif. , Aug. 8, 2024 /PRNewswire/ -- VESICA HEALTH, INC.
, a leading multi-omics liquid biopsy company committed to improving the management of hematuria patients and the early detection of bladder cancer, is excited to announce the formation of its Scientific Advisory Board (SAB). The SAB comprises a distinguished group of world-renowned bladder cancer experts, who will bring invaluable insights and expertise across all phases of operations, spanning research to clinical strategies, to enhance patient care. "We are honored to welcome these exceptional and accomplished bladder cancer leaders to Vesica Health's Scientific Advisory Board," stated Laura Caba , MPH, President of Vesica Health .
"In our commitment to supporting the clinical community and patients, we will rely on these experts. Their deep understanding of the unmet needs will guide us in our mission to elevate patient care and improve outcomes." "I am excited to join Vesica's Scientific Advisory Board and support their important mission to improve the early detection of bladder cancer," commented Sam S.
Chang , MD, MBA , Professor of Urology, Patricia and Rodes Hart Chair of Urologic Surgery and Chief Surgical Officer, Vanderbilt-Ingram Cancer Center at Vanderbilt University . "This Advisory Board brings together an esteemed group of peers, and I know we all look forward to collaborating with the management team to advance Vesica's clinical programs and our shared goal of improving bladder cancer detection.